Platform for *Plasmodium vivax* vaccine discovery and development

Sócrates Herrera Valencia1,2,3,*, Diana Carolina Rodríguez1,2, Diana Lucía Acero1,2, Vanessa Ocampo1,2, Myriam Arévalo-Herrera1,2

1Caucasico Scientific Research Centre, Cali, Colombia
2Centro Latino Americano de Investigación en Malaria, Cali, Colombia
3Instituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia

Plasmodium vivax is the most prevalent malaria parasite on the American continent. It generates a global burden of 80-100 million cases annually and represents a tremendous public health problem, particularly in the American and Asian continents. A malaria vaccine would be considered the most cost-effective measure against this vector-borne disease and it would contribute to a reduction in malaria cases and to eventual eradication. Although significant progress has been achieved in the search for Plasmodium falciparum antigens that might be used in a vaccine, limited progress has been made in the search for *P. vivax* components that might be eligible for vaccine development. This is primarily due to the lack of in vitro cultures to serve as an antigen source and to inadequate funding. While the most advanced *P. falciparum* vaccine candidate is currently being tested in Phase III trials in Africa, the most advanced *P. vivax* candidates have only advanced to Phase I trials. Herein, we describe the overall strategy and progress in *P. vivax* vaccine research, from antigen discovery to preclinical and clinical development and we discuss the regional potential of Latin America to develop a comprehensive platform for vaccine development.

Key words: malaria - *Plasmodium vivax* - vaccine platform - discovery - vaccine development - neglected disease - Latin America

On the American continent, an estimated 170 million people living in a total of 21 countries of the Latin America (LA) and Caribbean regions are continuously exposed to *Plasmodium vivax* and *Plasmodium falciparum* infections (Guerra et al. 2008, 2010). Approximately 60% of the malaria cases are reported in Brazil, whereas 40% of the cases are from Colombia (14.2%), Peru (8.8%), Venezuela (5.4%), Bolivia (1.9%) and Ecuador (1.1%). In addition, Haiti (2.8%), of the Caribbean region, and Central American countries, including Guatemala (3.8%), Panama (0.4%) and Honduras (1.5%), contribute to the overall malaria burden. In terms of *Plasmodium* species, approximately 74% of infections are caused by *P. vivax*, 25% by *P. falciparum* and the remaining 1% by *Plasmodium malariae*. The infections result in an estimated mortality rate of 1% (Guerra et al. 2010).

Significant regional efforts have been aimed at controlling malaria and the Global Malaria Eradication Program (GMEP) led to the elimination of, or significant reduction in, malaria outbreaks throughout the American continent by 1960 (Gabaldon et al. 1961, Gabaldon 1983). However, the decades that followed were characterized by a trend of increasing malaria transmission, with periodic epidemic outbreaks in some areas (Gusmão 1999, WHO 2010). At the beginning of the GMEP, countries such as Venezuela, Colombia, Peru and Panama had a significantly diminished number of malaria cases. However, for multiple reasons, control activities were not sustainable. Parasites and mosquitoes became refractory to antimalarial drugs and insecticides, respectively, leading to a malaria resurgence (Alonso et al. 2011, Najera et al. 2011). Despite the failure of the control measures to eradicate malaria in South America and the persistence of the disease in the whole American continent, countries such as El Salvador, Costa Rica, Guatemala and Nicaragua have witnessed a decrease of > 90% in malaria transmission over the last decade. A similar pattern has been observed in other regions worldwide, which has generated growing enthusiasm about the possibility of malaria elimination in multiple countries, including the Mesoamerican region (Feachem et al. 2009, ISM2015 2010).

While *P. falciparum* dominates malaria transmission on the African continent (90%), in the rest of the world, including LA, *P. vivax* is predominant (70%), with co-existence of both parasite species in numerous malaria-endemic regions (Mendis et al. 2009).

Although species co-existence simplifies some control activities, it makes others more difficult: vectors for both parasite species in a given region may be controlled in a similar fashion, but clinical manifestations, susceptibility to antimalarials, virulence, mortality and life cycle forms (development of hypnozoites in *P. vivax*) are different (Das et al. 2009). Moreover, the immune responses induced by both parasite species, the mechanisms of protection and factors involved with pathogenesis may be different. An additional complication is that in regions where more than one species is present, the control or elimination of one species could lead to an increase in the number of cases caused by the remaining species (Oliveira-Ferreira et al. 2010). Therefore, efforts...
to develop an effective malaria vaccine must consider the inclusion of components from both parasite species. The most advanced *P. falciparum* vaccine is undergoing Phase III testing and several others candidates are currently being assessed in Phases I and II. The most advanced *P. vivax* vaccine candidates, in contrast, have only been tested in Phase I trials and a few others are only now being tested in preliminary studies (Arévalo-Herrera et al. 2010, Crompton et al. 2010, Goodman & Draper 2010). It is likely that the current malaria epidemiological scenario would not benefit from a Phase III testing and several others candidates are only now being tested in preliminary studies (Arévalo-Herrera et al. 2010, Crompton et al. 2010, Goodman & Draper 2010).

Because of the high prevalence and epidemiological importance of *P. vivax* in LA region, as well as the potential for researchers from LA to contribute to the development of an effective malaria vaccine, attempts to establish proper conditions for accelerating the identification and characterisation of new *P. vivax* vaccine candidates are being made in Colombia and other countries of the region. The available facilities and strategies, as well as the current perspectives, are described here.

**Acquired immunity and evidence of malaria immune protection - Naturally-acquired immunity** - Despite the fact that mechanisms of malaria immune protection are only partially understood, it has been observed that natural immunity is progressively acquired during the first two decades of life in subjects residing in malaria-endemic regions (Collins & Jeffery 1999). If individuals are persistently exposed to malaria, they progressively develop milder clinical manifestations, lower parasitaemia levels and eventually asymptomatic infections. Sterile immunity, however, is never achieved (Bottius et al. 1996). The immunity that is acquired is species and stage specific (Cohen 1979), depends on continuous antigenic stimulation and will decrease rapidly in the absence of exposure to the parasite (Yount & Coggeshall 1949, Doolan et al. 2009). Clinical immunity significantly contributes to the decrease in the economic burden of the disease, as individuals exposed to malaria for long periods of time eventually develop an almost normal life activity. This provides indirect evidence for the feasibility of a malaria vaccine that would decrease morbidity and mortality.

Naturally-acquired immunity to malaria has been extensively documented in *P. falciparum* (Day & Marsh 1991, Doolan et al. 2009). Reports available on *P. vivax* infection in Papua New Guinea (PNG) indicate that there is a high transmission intensity. Therefore clinical immunity to *P. vivax* is acquired faster in young children than is immunity to *P. falciparum*. This is demonstrated by an increased ability of children to control *P. vivax* parasitaemia (Lin et al. 2010). In contrast, most malaria-endemic regions of LA have low, unstable malaria transmission, and therefore the acquisition of clinical immunity is likely different from that in PNG. It has been assumed that immunity is rarely acquired in areas with relatively low malaria transmission (Macdonald 1951). However, in studies conducted in the Amazon Basin of Brazil, a high frequency of subclinical infections with sub-patent parasitaemia occurred in all age groups with disease significantly decreasing with age (Alves et al. 2005, Coura et al. 2006, Suarez-Mutis et al. 2007, Ladeia-Andrade et al. 2009). In the Peruvian Amazon, despite low transmission and supervised administration of the recommended radical malaria cure regimen, patients with *P. vivax* infections remained sub-patent and asymptomatic for several consecutive months, until spontaneous clearance without treatment (Van den Eede et al. 2011). Similar observations were made in studies conducted in Colombia. The prevalence of sub-patent parasitaemias ranged from 0-33% regardless of age, based on thick smear assays in areas of high malaria transmission on the Pacific coast (Terrientes et al. 1994, González et al. 1997, Mendez et al. 2000, Osorio et al. 2004). In the northern area of Colombia (Tierralta, Cordoba), the prevalence of *Plasmodium* infection was approximately 18%, whereas the prevalence of asymptomatic infection as measured with polymerase chain reaction was 15% (Cucunubá et al. 2008). Although there is a lack of systematic studies in LA to determine the grade of clinical immunity and its correlation with age, the high prevalence of subclinical infection observed in LA suggests that individuals who are permanently exposed to malaria acquire a level of immunity that allows them to live a normal life. This may also explain the maintenance of low to moderate malaria transmission in LA.

Experimental studies have shown that sterile immunity can be achieved by different means. Retrospective analysis of data collected from patients who had received malaria therapy for the treatment of neurosyphilis during the first decades of the XX century showed that some strain-specific immunity can be developed, even after only the first parasite exposure. The development of species-specific immunity, in contrast, required several infectious exposures with heterologous strains (Collins & Jeffery 1999, 2004). Second, immunization of human malaria-naïve volunteers with irradiated malaria sporozoites (attenuated) has consistently been shown to confer sterile protection against experimental challenge with live sporozoite mosquito bites (Clyde 1990). Third, passive transfer of antibodies from hyper-immune malaria adults to malaria-naïve individuals has shown consistent parasite clearance of asexual blood stage parasites (Cohen et al. 1961, McGregor 1964, Sabchareon et al. 1991). Fourth, malaria-naïve subjects, as well as individuals from malaria-endemic communities, may be partially protected by vaccination with the RTS,S vaccine, a recombinant *P. falciparum* vaccine candidate based on the circumsporozoite (CS) protein (Aide et al. 2011, Olotu et al. 2011).

**Evidence of immunization-induced immunity** - Although it has been proposed that the intracellular development of the parasite is a mechanism to evade the immune response, immune factors are capable of eliminating intracellular parasites within both hepatocytes and red blood cells (Hoffman et al. 1996, Riley et al. 2006). The accepted theory of the last two decades has been that parasites can be targeted during the short extracellular time periods prior to hepatocyte invasion, erythrocyte reinvasion or gamete fertilization (Hoffman & Miller 1996, Herrera 2005, Girard et al. 2007). According to this concept, vaccines targeting the pre-erythrocytic stage would induce antibody-mediated
inhibition of hepatocyte invasion by sporozoites (Hollingdale 1990). Nevertheless, some antigens have been shown to delay the development of liver stage schizonts by parasites through cytolytic immune responses mediated by CD8+ lymphocytes or cytokines, such as gamma interferon (IFN-γ) (Rodrigues et al. 1991, Scheller & Azad 1995, BenMohamed et al. 2004, Hafalla et al. 2011). Given that tissue schizonts are asymptomatic and is followed by the clinical manifestations of the infection, inhibiting this phase may provide sterile immunity (Nussenzweig & Nussenzweig 1989, Richie & Saul 2002). During asexual parasite development, vaccines could induce specific antibodies that block merozoite invasion of erythrocytes (Holder 1996), facilitate erythroptagocytosis (Khushmith et al. 1982, La Raja 2002), induce complement-mediated erythrocyte lysis (Healer et al. 1997) or inhibit intraerythrocytic parasite development through soluble immune mediators, such as oxygen radicals that are released in response to antibody dependent cell inhibition (Bouharoun-Tayoun et al. 1995). It has been proposed that erythrocytic stage vaccines would not prevent blood infection and that they are intended simply to diminish the severity of the disease. However, there is the possibility that a highly effective vaccine targeting the asexual blood stage would block the invasion of the first-generation merozoite upon the burst of a liver schizont, and that this could occur prior to the appearance of clinical manifestations (Holder 1996, Lusingu et al. 2009). Furthermore, the parasite could be targeted during the fertilization process by antibodies that recognise gametocytes (Tsuboi et al. 2003, Dinglasan et al. 2007), thus blocking the sporogenic parasite development in the mosquito midgut.

**Strategies for malaria vaccine discovery - Classic strategies for parasite antigen discovery and production**
- Although malaria vaccine research has been conducted for several decades, the introduction of recombinant DNA technology and peptide synthesis in the early 1980s (Nussenzweig & Nussenzweig 1984, Miller et al. 1986), together with the development of long-term *P. falciparum* culture methods (Trager & Jensen 1976), greatly stimulated vaccine candidate discovery. Using these technologies, malaria antigen selection, expression and purification became more efficient and the first vaccine candidates were proposed (Nussenzweig & Nussenzweig 1989). Thereafter, parasite DNA obtained from in vitro cultures, infected animals, patients or mosquitoes allowed easy gene cloning and the generation of DNA expression libraries. Such libraries were further screened with semi-immune sera as well as with monoclonal antibodies in the search for antigenic proteins. Recombinant technology allowed the mass production of proteins that are suitable for use in large scale immunization (Mahanty et al. 2003).

The production of synthetic peptides has also contributed to malaria vaccine development, allowing the characterization of T helper cell (Herrera et al. 1992), CD8+ T cell (Arévalo-Herrera et al. 2002) and B cell epitopes (Arévalo-Herrera et al. 1998, Good & Doolan 2010).

In addition, mass production of asexual blood parasites from *P. falciparum* cultures contributed to the isolation of parasite strains that were able to develop mature, infective gametocytes in vitro (Ponndurai et al. 1982). The latter have not only facilitated the identification of relevant antigens on sexually differentiated parasites (gametocytes), but have also permitted the establishment of effective methods of infecting colonies of *Anopheles* mosquitoes (Gamage-Mendis et al. 1993, Toure et al. 1998, Solarte et al. 2011). This has made it possible to produce mature, viable and functionally active sporozoites (Ponndurai et al. 1989) that can be used to assess the capacity of antibodies to block parasite transmission from human to mosquito, ex vivo (Hurtado et al. 1997, Sattabongkot et al. 2003, Arévalo-Herrera et al. 2005c, 2011a, Diallo et al. 2008, Solarte et al. 2011).

Unfortunately, the lack of a method to continuously cultivate *P. vivax* has made this process significantly more complex, for several reasons. First, parasites have to be obtained directly from patients or from infected non-human primates, which makes the process expensive and cumbersome (Collins et al. 1986, Arévalo-Herrera et al. 2005b). Second, *P. vivax* has a high propensity for reticuloocyte invasion and parasitaemias in both humans and monkeys, which seldom exceeds 1% (Herrera et al. 2002, Jordán-Villegas et al. 2005). Consequently, only a limited number of sites that are located close to endemic areas have access to both human *P. vivax*-infected blood samples and laboratories with conditions to effectively produce different *P. vivax* parasite forms (i.e., asexual, gametocytes or sporozoites) (Mendis et al. 1987, Sattabongkot et al. 1991, Salas et al. 1994, Ramsey et al. 1996, Carter et al. 2000, McClean et al. 2010, Solarte et al. 2011).

Because of these constraints, only a few *P. vivax* antigens with vaccine potential have been identified (Herrera et al. 2007, Arévalo-Herrera et al. 2010). Stage-specific antigens described to date are as follows: the CS protein (McCarthy & Clyde 1977) and the sporozoite surface protein/trombospondin related adhesive protein (SSP/ TRAP) (Templeton & Kaslow 1997), which are present at the pre-erythrocytic stage of the parasite, the Duffy binding protein (DBP) (Fang et al. 1991, Chitnis & Miller 1994), the merozoite surface protein (MSP)-1 (Del Portillo et al. 1991) and the apical membrane antigen (AMA)-1 (Kocken et al. 1999), which are present at the asexual erythrocytic stages, and the Pvs25 and Pvs28, which are present in stages developed in the mosquito midgut, i.e., ookinetes/oocysts (Tsuboi et al. 1998) (Figure).

Although there have been no sexually differentiated erythrocytic stage (gametocyte) antigens reported to date, several genes from both gametocytes and the sporogonic cycle have been identified. These have yet to be expressed as proteins that can reach preclinical studies (Moreira et al. 2004).

**Pre-erythrocytic vaccines** - The CSP has been the most widely studied malaria protein. It is abundantly expressed on the sporozoite surface and it is involved in parasite invasion of hepatic cells. It was cloned in 1985 (Arnot et al. 1985) and several studies examining its characterization, its immunogenicity in animals (see *P. vivax preclinical vaccine studies*) and its safety, tolerability and immunogenicity in clinical studies have been conducted (see *Clinical P. vivax vaccine studies*).
SSP2/PvTRAP is a protein present on the surface and in the micronemes of sporozoites and the liver-stages of the parasite and it is involved in motility and cell adhesion (Sultan et al. 1997). It was first cloned in 1997 (Templeton & Kaslow 1997), and its immunogenicity and protective efficacy in rodents and *Aotus* monkeys has been tested (Castellanos et al. 2007). It has also been shown to be effective in mice as a DNA vaccine (Rogers et al. 1999) (see Preclinical studies using *P. vivax* subunit vaccines: immunogenicity and protective efficacy).

The antigenicity of the CSP protein has been widely studied in malaria-endemic regions of LA, particularly in Colombia (Herrera et al. 1997, 2004), Brazil (Kremsner et al. 1992, Curado et al. 1997, Oliveira-Ferreira et al. 2004, Arruda et al. 2007) and Mexico (Mota et al. 1996).

In these studies, several CS-derived synthetic peptide fragments corresponding to the N-terminal, C-terminal and central repeat domain peptide (R) have been tested using sera from subjects from LA-endemic areas who showed significant seropositivity rates for this protein, specifically for the R fragment (Herrera et al. 2004, Oliveira-Ferreira et al. 2004, Arruda et al. 2007). In addition, when sera from San Luis Potosí, Mexico (Mota et al. 1996) and Colombia was tested against synthetic peptides corresponding to the VK210 and VK247 variants of CS, recognition of the VK210 variant was higher than recognition of the VK247 variant (Arévalo-Herrera et al. 1998, González et al. 2001).

Concerning cellular responses, CD8+ T-lymphocyte responses to long synthetic peptides (LSP) that corresponded to the C-terminal region of CSP induced the production of considerable levels of IFN-γ. Thus, this region has the potential to induce CSP-specific cellular immune responses (Arévalo-Herrera et al. 2002).

Together, these studies confirm the antigenicity of the protein and the prevalent recognition of the repetitive region, and they demonstrate the induction of cellular immune responses by the C-terminal peptide. These findings have important implications for development of *P. vivax* vaccine.

Vaccines for the asexual blood stages - DBP, MSP-1 and AMA-1 have received considerable attention as vaccine candidates. DBP is considered an antigen with great vaccine potential due to the fact that *P. vivax* invasion of erythrocytes depends on the interaction of this protein with the Duffy blood group (Fy) antigen. As a result, individuals who lack Fy antigen (Fy-) are naturally protected from *P. vivax* blood infection (Herrera et al. 2005b). This antigen has been tested with sera from PNG, the Brazilian Amazon and Colombia (Herrera et al. 2005b, King et al. 2008, Cole-Tobian et al. 2009, Maestre et al. 2010). In different populations of the Brazilian Amazon, anti-DBP antibodies were detected and shown to correlate with long-term exposure to malaria (Ceravolo et al. 2009, Souza-Silva et al. 2010). In Colombia, despite the low transmission of *P. vivax* infection, a high prevalence of anti-DBP antibodies (40%) was observed in sera from Fy+ individuals from the Pacific coast, particularly in those > 40 years old (Michon et al. 1998). This is in contrast to recent studies in the northern endemic region where only 9% of the Fy+ sera showed reactivity against a DBP recombinant protein (Maestre et al. 2010).

MSP-1 is a protein expressed on the merozoite surface of all malaria species. Two highly conserved MSP-1 fragments, the PvMSP-1-1 (located at the C-terminal) and the PvMSP-1-200L (Pv200L located at the N-terminal), have been extensively studied and proven to be highly immunogenic (Soares & Rodrigues 2002, Valderrama-Aguirre et al. 2005, Bargieri et al. 2010, Storti-Melo et al. 2011). Studies using sera from individuals naturally exposed to *P. vivax* in the Brazilian Amazon showed that 50-90% of sera from naturally exposed individuals contain antibodies against these proteins (Soares et al. 1997, Bastos et al. 2007, Storti-Melo et al. 2011). Similarly, the majority of individuals from Buenaventura, a malaria-endemic area of Colombia, presented antibodies to Pv200L (Valderrama-Aguirre et al. 2005), supporting the potential of this fragment as a vaccine target.

The AMA-1 protein is expressed initially in the merozoite micronemes, and further translocates to the parasite surface during erythrocyte invasion where it is involved in the apical re-orientation of merozoites after initial attachment. This protein is highly immunogenic during natural infection in humans and it displays limited polymorphism in Brazil (Rodrigues et al. 2003). The extracellular domain, DII, is the most frequently recognized domain (Mufalo et al. 2008).

Transmission blocking antigens - Pvs25 and Pvs28 are highly conserved ookinet surface antigens composed of four tandem epidermal growth factor-like domains. They are putatively anchored to the parasite surface by a glycosyl-phosphatidyl-inositol moiety (Toure et al. 1998). Cloning and expression of these genes as recombinant proteins has allowed their characterization and use as transmission-blocking vaccines. They have been tested in animal models, allowing the completion of Phase I clinical studies (see Preclinical studies using *P. vivax* subunit vaccines: immunogenicity and protective efficacy and Phase I clinical trials - CS).
Novel approaches for parasite antigen discovery - Since the *P. falciparum* genome sequence was completed and reported in 2002 (Gardner et al. 2002), and that of *P. vivax* more recently (Carlton et al. 2008, Dharia et al. 2010), a substantial amount of information about these two parasites has become available. Comparative studies have shown that these *Plasmodium* species have the potential to express approximately 5,000 putative proteins of which 77% are orthologous with proteins in other malaria species. Despite the enormous efforts for malaria vaccine development during the past decades, vaccine candidates represent no more than 0.1% of the complete *P. vivax* predicted proteome. However, during the last few years, studies describing the *P. falciparum* and *P. vivax* transcriptomes (Bozdech et al. 2008, Westenberger et al. 2009), including a few variant surface antigens from the *Plasmodium* interspersed repeat multigene family (Cunningham et al. 2010), have been identified and progress has been made in understanding the parasite transcription process, as well as in elucidating the *P. falciparum* intraerythrocytic transcriptoric/proteomic process (Foth et al. 2011). All of the currently available information has been integrated into an accessible data base, PlasmoDB (Aurrecoechea et al. 2009), which provides substantial information for the selection of antigens with vaccine potential. Among them, several novel *P. vivax* theoretical adhesins and adhesion-like molecules have been recently identified (Ansari et al. 2008), which would expand the list of potential *P. vivax* vaccine candidates.

Pilot studies aimed at providing a more efficient system for *P. vivax* antigen discovery have been conducted. In a cooperative effort between the Malaria Vaccine and Drug Development Centre (MVDC) in Cali, Colombia, and The Institute for Genomic Research in Rockville, Maryland, a first approach was performed to identify novel antigens with vaccine potential. A wide *P. vivax* genome screening was conducted. A total of 18 genes were selected based on criteria indicating their possible expression on the surface of sporozoites. Genes were cloned, expressed in eukaryotic cells and tested to determine their potential to stimulate B and T cell responses in vitro. Based on the fact that *Fy* individuals who are permanently exposed to *P.* vivax malaria in endemic regions develop immune responses mainly to pre-erythrocytic stage antigens (Herrera et al. 2005b, Wang et al. 2005), sera and peripheral blood mononuclear cells (PBMC) were obtained from individuals residing in malaria-endemic areas of Colombia to test the antigenicity of these proteins (Herrera et al. 1992, Arévalo-Herrera et al. 1998).

To assay B cell responses, transient transfection of human embryonic kidney cells (HEK-293) with known sporozoite (CSP, SSP2), blood stage (AMA-1 and MSP-1) and novel genes was carried out. Transfected cells expressing these antigens were tested with semi-immune sera. Likewise, to determine the efficacy of T cell responses elicited by these and other selected antigens, autologous PBMC were transfected and used as antigen-presenting cells (APCs) to autologous mononuclear cells (T cells). The T cell response was measured by IFN-γ production. Novel antigens that elicited cellular and humoral responses were considered to be eligible for further evaluation of their vaccine potential (Wang et al. 2005, Herrera et al. 2007).

Recently, a group of 11 novel genes and two other known antigens (CS, MSP-1) were assessed using the methodology described above. In this study, HEK-293 cells that were transfected with each gene were efficiently recognized by sera of individuals from endemic areas of Colombia. Again, autologous PBMCs were transfected with the genes and used as APCs for T cells from individuals of endemic areas. As determined by measuring IFN-γ production through the enzyme-linked immunosorbent spot assay, all genes elicited specific, cellular immune responses. In order to further determine the immunogenicity of these antigens in rodents, a proof-of-principle study was performed using six of these genes cloned into an expression vector containing a cytomegalovirus promoter (pcDNA3.1 D/V5-HisTOPO, Invitrogen). These vectors were used as DNA vaccines. BALB/c mice were immunized with four novel and two known (CS, MSP-1) genes. Sera of vaccinated mice were tested for a response by immunofluorescence (IFAT) and enzyme linked immunosorbent assay (ELISA), and the results indicated that most vaccinated animals produced specific humoral responses after the second or third immunization (unpublished data). In addition, all genes induced T cell responses. A screening approach like this one would facilitate the identification of genes/antigens capable of inducing predominantly T cell responses. This would be particularly useful in terms of identifying IFN-γ responses, which are known to be crucial for protection during the pre-erythrocytic phase of infection (Hafalla et al. 2011).

By means of collaboration between MVDC and the Institute of Biochemistry at the University of Lausanne (Switzerland), a bioinformatic search was combined with chemical peptide synthesis and serological screening for rapid identification of novel vaccine candidates. Based on the observation that α-helical protein domains are present in several *P. falciparum* malaria antigens and are targets of antibodies (B cell epitopes), a comprehensive bioinformatic search was performed on the *P. falciparum* genome. A total of 100 segments present on pre-erythrocytic parasite stages were identified and 93 of these were chemically synthesized, purified and analyzed by mass spectrometry (MALDI-TOF). All peptides appeared to be antigenic, as each was recognized based on ELISA conducted with sera from individuals from malaria-endemic areas of Colombia, Burkina Faso and Tanzania. Peptide-specific antibodies were purified from these immune sera using affinity chromatography and they were tested for recognition of native proteins in IFAT. *P. falciparum* parasitized red blood cells were recognized by antibodies purified from 18 human sera (Villard et al. 2007).

A similar approach is currently being used for *P. vivax* antigen discovery. A total of 50 *P. vivax* genes that are orthologous to *P. falciparum* have been identified and processed as described. Antigenicity of these peptides is being analyzed with sera of individuals from endemic areas of Colombia, PNG and Burkina Faso.
liminary ELISA results have shown that all 50 peptides
are antigenic, but significant variability in recognition
has been observed. Specific anti-peptide antibodies have
been purified and their protective efficacy is being as-
essed through passive transfer experiments in P. vivax-
infected primates. Additionally, the selected peptides are
being evaluated for their immunogenicity in BALB/c
mice and preclinical studies will be conducted in Aotus
monkeys to evaluate the peptides protective efficacy.

Recently, the construction of LSP (up to 185 residues)
for vaccine development has contributed to the rapid
production of clean, functional, synthetic proteins con-
taining fragments that have induced specific immune
responses in preclinical and clinical studies (Perlaza et
al. 2001, Herrera et al. 2005a, 2011, Corradin et al. 2010,
Olugbile et al. 2010, Arévalo-Herrera et al. 2011b). Despite limited financial support, significant ad-

vances have been made in the discovery and develop-
ment of potential P. vivax vaccines. Unfortunately, in
contrast to P. falciparum, genome wide studies on P. vivax are still limited. This is due to the current lack of
continuous cultures and to the limited amount of DNA
that can be derived from human blood draws.

Mosquito components as candidates for malaria vac-
cine development - Another proposed vaccine strategy
does not target parasite components, but instead targets
mosquito components. Targeted components are essential
for mosquito survival or for the vector-parasite inter-
action. These components include glycans (carbohydrates),
glycoproteins and enzymes, including the Anopheles gambiae aminopeptidase N (AgAPN1). The inhibition of this
enzyme by anti-AgAPN1 IgG has been shown to strongly
inhibit both Plasmodium berghei and P. falciparum de-
velopment in different mosquito species, suggesting an
important role for this protein in the ookinetie invasion of the mosquito midgut (Dinglasan & Jacobs-Lorena 2008). Targeting vital mosquito molecules or parasite host-cell
interactions could lead to the blockage of human to hu-

P. vivax preclinical vaccine studies - Animal models
Rodents and non-human primates are the preferred animal
models for malaria vaccine preclinical testing (Stowers &
Miller 2001, Herrera et al. 2002). Four rodent malaria spe-
cies [P. berghei, Plasmodium chabaudi (subspecies cha-
baudii and adami), Plasmodium vinckeii, and Plasmodium
yoelii] have been isolated from wild African rodents and
are currently being used for preclinical research. While
each model will not provide enough information individu-
ally to reliably extrapolate the results to humans, together
these models will provide relevant information about the
antigens and immune mechanisms and about the immu-
no-pathogenesis of malaria (Taylor-Robinson 2010).

New World non-human primates have proven to be a
very valuable model for malaria vaccine and drug test-
ing (WHO 1988, Herrera et al. 2002). Among them, pri-
mates from the Aotus and Saimiri genera are the most
extensively used for malaria research and they are still
abundant in several countries of LA (Collins 1992).

These primates are currently considered to be endan-
ergered and some countries have banned their exporta-
tion to other countries or restricted their capture even
for scientific purposes. Nonetheless, a number of pri-
mate centres located in LA provide a valuable resource
for vaccine studies (Table). Currently, there are multiple
primate centres in Panama, Colombia, Peru and Brazil
that harbour these genera and would allow significant
vaccine progress if funds were available.

Both Aotus and Saimiri monkeys are susceptible to
experimental infection with previously-adapted, human
Plasmodium strains, but there are some susceptibility
differences (Young et al. 1966). Aotus lemurinus gri-
seimembra appears to be the New World monkey spe-
cies most susceptible to infection with human malaria
parasites. They have been shown to be susceptible to a
series of isolates including the P. falciparum Santa Lucia
and the P. vivax Salvador I (Sal I) strains. Both para-
site species are able to produce mature gametocytes that
are infective to Anopheles mosquitoes and able to pro-
duce sporozoites (Salas et al. 1994, Hurtado et al. 1997,
Jordán-Villegas et al. 2005), thus allowing studies with
all P. falciparum and P. vivax parasite stages.

Preclinical studies using P. vivax subunit vaccines: in-
munogenicity and protective efficacy - Pre-eryth-
rocytic stages - Several preclinical studies have been
carried out to assess the safety and immunogenicity of
PvCSP formulations (Collins 1990, Stowers & Miller
2001, Arévalo-Herrera et al. 2011b). After detailed im-
munological characterization of PvCS that included
mapping of relevant B and T cell epitopes, mapping of
three LSP-containing fragments of the N-terminal and
C-terminal regions and mapping of R of the PvCS, vari-
ous vaccine formulations were tested for immunogenic-
ity in mice and Aotus monkeys (Herrera et al. 2004,
Arévalo-Herrera et al. 2011b). In Aotus, the three LSP
fragments that were formulated with Montanide ISA 720
(Seppic, France) induced strong antibody responses. An-
tibodies recognized the native protein on the sporozoite
and Aotus PBMCs responded with in vitro production
of IFN-γ (Herrera et al. 2004, Arévalo-Herrera et al.
2011b). Monkeys responded preferentially to the N pep-
tide with both adjuvant formulations (Herrera et al. 1997,
These studies provided the impetus for the use of these
vaccine formulations in Phase I clinical trials (see Clin-
ical P. vivax vaccine studies).

A recombinant version of the P. vivax CSP, which
contained a R composed of both VK210 (South Korean
Type I) and VK247, was produced in Escherichia coli
and used for immunogenicity studies in mice. BALB/c
mice were inoculated with recombinant CSP formulated
with Montanide ISA 720, Montanide ISA 51, and in-
complete Freund’s adjuvants, and these formulations were
highly immunogenic and elicited antibodies that agglu-
tinated live sporozoites (Bell et al. 2009).

P. vivax SSP2/TRAP has been tested in mice and
monkeys and was shown to induce high levels of specific
antibodies in both animal models (Rogers et al. 1999).
More recently, LSP formulated with Montanide ISA 720 was tested in BALB/c mice and *Aotus* monkeys and it resulted in specific antibody responses in both animal species. Although *Aotus* monkeys showed partial protection against challenge with *P. vivax* sporozoites, no further studies have been reported with this or other SSP2/TRAP constructs (Castellanos et al. 2007).

Asexual blood stages - *P. vivax* merozoites have been shown to require interaction with Fy antigen for reticulocyte invasion through DBP and the antibody-mediated immune blockage of this interaction represents a promising mechanism for vaccine development. Several preclinical studies have been conducted with *Pv*RII-DBP, a polymorphic and functional domain located in the N-terminal region of the DBP. Immunogenicity studies in mice showed that recombinant *Pv*RII formulated with any of five adjuvants elicited high titres of antibodies. Two of the formulations [Montanide ISA 720 and AS02A (GlaxoSmithKline)] were highly effective at inducing antibodies capable of blocking *Pv*RII binding to erythrocytes in a functional assay (Yazdani et al. 2004). Studies in rhesus monkeys provided evidence that these proteins were also highly immunogenic when formulated with Montanide ISA 720 and AS02A, and antibody titres correlated with in vitro binding inhibition assays (Moreno et al. 2008).

Immunization of *Aotus* monkeys formulated with Freund's adjuvant as well as with Montanide ISA 720 showed high immunogenicity. Monkeys immunized with *Pv*RII formulated with Freund's adjuvant showed partial protection against intravenous challenge of animals with *P. vivax* asexual blood forms and had higher antibody titres than monkeys immunized with the Montanide ISA 720 formulation. Despite being immunogenic, the Montanide ISA 720 formulation did not induce protection (Arévalo-Herrera et al. 2005a, Chitnis & Sharma 2008). Notwithstanding the discouraging results, this protein is currently being proposed as a vaccine candidate for clinical development due to its functional role (Moorthy & Hill 2002, Alonso et al. 2011).

The antigenicity of the MSP-1 fragments has been demonstrated in several studies using different regions of this protein (*Pv*MSP1 N and C-terminal regions and *Pv*200L) (Valderrama-Aguirre et al. 2005, Yeom et al. 2008). Additionally, *P. vivax* MSP-1 has elicited partial protection in *Saimiri boliviensis* (Stowers et al. 2001).

BALB/c mice and *Aotus* monkeys immunized with a recombinant *Pv*200L protein that was produced in *E. coli* showed high IgG antibody titres that cross-reacted with *P. vivax* parasites. *Pv*200L formulated with Freund's adjuvant displayed unexpectedly high antibody responses and recognition of parasite antigens in vitro. Immunized primates were partially protected against an experimental heterologous challenge with *P. vivax*, as measured by lower and self-limiting parasitaemias and protection against malaria (Valderrama-Aguirre et al. 2005).

A nucleic acid vaccine has been developed using the *P. vivax* AMA-1 gene, which induces high antibody titres in mice (Rogers et al. 1999). Additionally, a recombinant *P. vivax* AMA-1 protein produced in *Pichia pastoris* and adjuvanted with SBAS2 proved to be highly immunogenic in rhesus monkeys, inducing high IgG antibody titres (Kocken et al. 1999).

| TABLE |
| Latin American primate centres |
| Primary species |

<table>
<thead>
<tr>
<th>Primate centre</th>
<th>Country</th>
<th>Saimiri sciureus</th>
<th>Aotus</th>
<th>Aotus species</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gorgas Memorial Laboratory/ Gorgas Memorial Institute of Health Studies, Panama</td>
<td>Panama</td>
<td>+</td>
<td>+</td>
<td><em>Aotus lemurinus lemurinus</em>, <em>Aotus trivirgatus</em></td>
<td>Rossan et al. (1975), Inselburg et al. (1991), Galinski et al. (1992)</td>
</tr>
<tr>
<td>Centre of Reproduction and Conservation of Non Human Primates/Universidad Nacional Mayor de San Marcos, Iquitos</td>
<td>Peru</td>
<td>+</td>
<td></td>
<td><em>Aotus nancymai</em>, <em>Aotus vociferans</em></td>
<td>Gozalo and Montoya (1990), Montoya et al. (1994)</td>
</tr>
<tr>
<td>Fiocruz Primate Centre, Rio de Janeiro</td>
<td>Brazil</td>
<td>+</td>
<td></td>
<td></td>
<td>Andrade et al. (2004), Alves et al. (2010)</td>
</tr>
<tr>
<td>National Primate Centre/ Fundação Nacional de Saúde, Belém</td>
<td>Brazil</td>
<td>+</td>
<td>+</td>
<td><em>Aotus infilatus</em></td>
<td>Carvalho et al. (2000, 2004, 2005)</td>
</tr>
</tbody>
</table>
Transmission blocking vaccines - Both Pvs25 and Pvs28 have been expressed as recombinant proteins in Saccharomyces cerevisiae and have been shown to be highly immunogenic and to induce blocking antibodies in animal models (Arévalo-Herrera et al. 2005b). Additionally, a recombinant Pvs25 formulated with Montanide ISA 720 has been tested in Aotus monkeys and it elicits antibodies with transmission-blocking activity and complete inhibition of parasite development in Anopheles albimanus mosquitoes fed with P. vivax-infected human blood by artificial membrane feeding assays (Arévalo-Herrera et al. 2005b). No vaccine studies using antigens expressed on the P. vivax gametocytes have been reported.

Preclinical studies using P. vivax irradiated sporozoites - One of the most valuable malaria vaccine models is the vaccination of human and various animal species with radiation-attenuated sporozoites (Clyde 1990). Numerous trials have been conducted with P. falciparum and with rodent malaria species, but only two volunteers have been vaccinated with P. vivax irradiated sporozoites. Although this vaccination system has repeatedly demonstrated the possibility of inducing sterile immunity in malaria and has become the malaria vaccine gold standard, until recently this vaccine strategy was not considered an option for mass production.

Recently, Sanaria Inc has embarked in the production of a viable, metabolically active, cryopreserved, radiation-attenuated P. falciparum sporozoite vaccine for human use (Hoffman et al. 2010). Although, it is too early to assess the feasibility of this strategy for industrial mass production or to evaluate the protective efficacy of this vaccine candidate in humans, it is clear that such a system would not be applicable for P. vivax because a method for continuous in vitro culture of this species is not available. In preparation to establish this system in humans, a preclinical study was recently conducted in Colombia in which Aotus monkeys were used in a dose-escalating study: groups of animals were subjected to two, five and 10 intravenous injections of P. vivax irradiated sporozoites (10⁴ dose). After vaccination, animals were challenged with 10⁴ viable P. vivax sporozoites. Aotus vaccinated 10 times were partially protected from infection, whereas those receiving fewer attenuated parasite doses were not protected (Jordán-Villegas et al. 2011). Although this model may require improvement, it represents a valuable experimental system to study mechanisms of protection against the P. vivax pre-erythrocytic phase and it may be complementary to studies in human (see Prospects for vaccination of human volunteers with P. vivax irradiated sporozoites).

Clinical P. vivax vaccine studies - In contrast to the number of P. falciparum vaccine candidates that have undergone clinical testing, only two P. vivax vaccine candidates have been tested in Phase I trials and none have progressed to clinical Phases II and III (Figure).

Phase I clinical trials - CS - Two clinical trials to assess the safety, immunogenicity and tolerability of P. vivax CS vaccine candidates based on LSP have been conducted at MVDC. The first trial tested three synthetically peptides, N, R or C of the CS protein, formulated with Montanide ISA 720. The second trial assessed varying doses of a mixture of three LSP (N, R and C peptides) formulated with Montanide ISA 720 or Montanide ISA 51. In both trials, antibodies to the three peptides recognized P. vivax sporozoites in an immunofluorescent antibody test and PBMC from most immunized volunteers (> 90%) also produced IFN-γ upon in vitro peptide stimulation (Herrera et al. 2005a). Vaccines adjuvanted with Montanide ISA 51 showed higher sporozoite protein recognition and IFN-γ production (Herrera et al. 2011). Both vaccines proved to be immunogenic, safe and well tolerated, with no serious adverse events (AE) reported.

Pvs25 - Thus far, two Phase I clinical trials have been conducted using Pvs25. One was a dose-escalating trial conducted using a recombinant Pvs25 expressed in S. cerevisiae, formulated with Alhydrogel®. This was called Pvs25H. AE related to vaccination were mild or moderate in severity and no serious AE were reported. The formulation induced antibody titres with transmission blocking activity in an antibody concentration-dependent manner and antibody remained detectable in most volunteers for a year after the first vaccination (Malkin et al. 2005). The second study assessed the safety and immunogenicity of recombinant PfS25 and Pvs25 vaccine candidates formulated with Montanide ISA 51. Despite the elicitation of serum anti-PfS25 antibody responses with transmission blocking activity, this trial had to be stopped when half of the volunteers developed local AE and the presence of a few systemic serious AE (Wu et al. 2008).

Preparation for Phase II clinical trials - Prospects for Phase II trials with P. vivax CS protein - Based on the success of the previous Phase I trials conducted with the PvCS peptide-based vaccine, efforts are being made to advance to Phase II studies in which the protective efficacy of these vaccine formulations would be assessed. Recently, two Phase II P. vivax sporozoite challenge trials have been performed to assess safety and to determine the minimal sporozoite effective dose. A total of 34 malaria-naïve volunteers have been exposed to two-10 infective mosquito bites. All volunteers developed pre-patent periods ranging from nine-16 days, with a mean of 10.2 days. Treatment was administered at detection of patent parasitaemia by thick blood smear. All volunteers successfully recovered after the treatment and no parasite relapses were documented in a two year follow-up period. No serious AE were reported (Herrera et al. 2009, 2011). A Phase II sporozoite challenge study to compare the responses of naïve and pre-immune individuals to sporozoites after two-four bites by infected A. albimanus is currently being planned at MVDC. The success of this study would allow comparative analysis of the protective efficacy of vaccination of naïve and preimmune individuals with the PvCS.

Prospects for vaccination of human volunteers with P. vivax irradiated sporozoites - Based on the successful preclinical studies conducted in Aotus monkeys with P. vivax irradiated sporozoites that were described in sec-
tion Preclinical studies using *P. vivax* irradiated sporozoites (Jordán-Villegas et al. 2011), and in view of the scarcity of data for this malaria species, a Phase I/II clinical trial is being prepared in Colombia to vaccinate naïve, human volunteers with *P. vivax* irradiated sporozoites. The aim of this study, sponsored by the National Heart, Lung and Blood Institute, is to determine the reproducibility of this model in *P. vivax* and to investigate the mechanisms of protection and the antigens targeted by protective immune responses. Reagents (sera and cells) derived from the vaccinated volunteers would be stored and used for *P. vivax* antigen discovery.

Establishment of field sites for further Phase III clinical trials - There are current efforts aimed at establishing field sites for Phase II and III vaccine studies in the LA region. For this purpose, the Centro Latino Americano de Investigación en Malaria (CLAIM), a research centre established with support from the National Institute of Allergy and Infectious Diseases, will significantly contribute to the goal of establishing field sites for malaria vaccine testing. CLAIM initially consisted of research groups and field sites in Colombia, Guatemala, Panama and Peru, but will extend its activities to other countries of South and Central America. This will increase our understanding of malaria epidemiology, vector biology, vector control and the clinical features of malaria, with the aim of contributing to malaria control and elimination in the region. Given that vaccines would represent a useful tool for malaria elimination, CLAIM will concentrate its efforts on studying the immune responses to novel and classical *P. vivax* antigens and will prepare sites for future *P. vivax* vaccine testing.

Conclusions and perspectives - Thus far, only a limited number of *P. vivax* antigens, i.e. PvCS and Pv25, have been adequately characterized to enter the process of preclinical and Phase I studies. Part of the effort to obtain novel vaccine candidates includes the combination of bioinformatics tools with chemical peptide synthesis and serological characterization.

In spite of the progress in genomic and proteomic technology, a lack of funding remains. Sustained efforts are needed for identification of novel antigens that could serve as vaccines candidates for testing in preclinical and clinical studies.

In order to be able to move forward in the development of the currently available vaccine candidates, and in preparation for the testing of novel compounds, it is critical to increase the efforts to develop long-term *P. vivax* culture methods. This resource would advance the standardization of a challenge model system and this is a necessary step to advance to Phase II clinical *P. vivax* vaccines trials.

Greater efforts and resources are urgently needed not only in the improvement of the immunologic and safety profiles of the currently available *P. vivax* vaccine candidates, but also in research and testing for new compounds that can help to advance development of an effective *P. vivax* vaccine.

ACKNOWLEDGEMENTS

To Dr Mark James, for critical reading of the manuscript.

REFERENCES


Clyde DF 1990. Immunity to *falciparum* and *vivax* malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. *Bull World Health Organ* 68: 9-12.


